The independent specialty pharmacy, the nation’s largest, said late Friday that the offering could raise about $200 million, depending on market conditions.
Last October, Diplomat completed an initial public offering of about 15 million shares on the New York Stock Exchange, raising about $145 million.
Diplomat said that with the new offering, to be made by prospectus, it expects to raise about $100 million of gross primary proceeds to be used for working capital and other general corporate purposes, which may include debt repayment and/or future acquisitions. The selling shareholders and certain option holders whose options will be repurchased by the company will receive the remaining $100 million of gross proceeds expected to be raised in the offering. Diplomat will not receive any proceeds from shares of common stock to be sold by the selling shareholders.
Serving all 50 states, Flint, Mich.-based Diplomat specializes in medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV and specialized infusion therapy, among other serious or long-term conditions.